This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Christopher Wild | |
|---|---|
| Name | Christopher Wild |
| Birth date | 1949 |
| Birth place | Glasgow |
| Nationality | United Kingdom |
| Occupation | Epidemiologist |
| Known for | Cancer epidemiology, International Agency for Research on Cancer |
| Alma mater | University of Glasgow, University of Oxford |
| Employer | International Agency for Research on Cancer, University of Leeds, University of Oxford |
Christopher Wild
Christopher Wild is a British epidemiologist noted for leadership in cancer epidemiology and global cancer research coordination. He served as Director of the International Agency for Research on Cancer and has held senior posts at major research institutions, influencing policy at organizations such as the World Health Organization and national research councils. His work spans molecular and environmental determinants of cancer, large-scale cohort studies, and the development of international research infrastructures.
Born in Glasgow, Wild attended primary and secondary education within Scotland before matriculating at the University of Glasgow where he studied medicine and public health. He pursued postgraduate training at the University of Oxford and undertook specialist epidemiology training that connected him with research groups in London and Leicester. Early mentors included figures associated with the Medical Research Council and collaborators from the Cancer Research UK network, shaping his trajectory toward population-based cancer research.
Wild's academic career includes appointments at the University of Leeds and later senior roles at the International Agency for Research on Cancer in Lyon. At Leeds he contributed to the establishment of prospective cohort studies and case–control investigations aligned with teams from the Wellcome Trust and the European Commission research programmes. As Director of the IARC, Wild oversaw multinational monograph evaluations and coordinated work with the World Health Organization, International Atomic Energy Agency, and regional agencies across Asia, Africa, and the Americas. His research integrated biomarker discovery with epidemiologic methods developed in consortia such as the European Prospective Investigation into Cancer and Nutrition and collaborations with the National Institutes of Health.
Wild advanced methodologies for exposure assessment, molecular epidemiology, and the interpretation of environmental carcinogens. He played a central role in the IARC Monographs programme that evaluated agents across sectors including occupational, lifestyle, infectious, and chemical exposures, collaborating with scientists from the International Labour Organization, Food and Agriculture Organization, and national regulatory bodies. His publications include synthesis reports on global cancer burden with contributors from the Global Burden of Disease collaboration, systematic reviews informing tobacco control policy, and methodological papers on biomarker standardization with partners at the European Commission Joint Research Centre and the World Health Organization Laboratory networks. Wild authored and co-authored influential articles in journals such as The Lancet, International Journal of Epidemiology, and Cancer Epidemiology, Biomarkers & Prevention, addressing topics from population attributable fractions to molecular signatures linking infectious agents and neoplasia. He contributed to guidelines used by the National Cancer Institute and advisory frameworks adopted by the Organisation for Economic Co-operation and Development.
Wild's work has been recognized by awards and honorary degrees from institutions including the University of Glasgow, University of Oxford, and international academies. He has received medals and distinctions from societies such as the European Society for Medical Oncology affiliate organisations, the Royal Society of Edinburgh fellowship nominations, and prizes awarded by cancer research charities including Cancer Research UK. National and international bodies like the World Health Organization and the International Agency for Research on Cancer acknowledged his leadership with appointments to honorary advisory lists and lifetime achievement recognitions.
Wild has held advisory positions for the World Health Organization, served on committees for the European Commission, and participated in panels convened by the National Institutes of Health and the National Cancer Institute. He has been a member of editorial boards for journals tied to the International Agency for Research on Cancer and served on grant review panels for the Wellcome Trust and national research councils in the United Kingdom and European Union. Wild chaired or co-chaired expert working groups for the IARC Monographs, contributed to policy dialogues with the World Bank, and engaged with public-private partnerships involving the Bill & Melinda Gates Foundation on global health research priorities.
Wild resides between research hubs in Lyon and the United Kingdom, maintaining links with academic centres such as the University of Leeds and the University of Oxford. His legacy includes strengthened international capacity for cancer surveillance, harmonized protocols for biospecimen collection used by consortia like the European Prospective Investigation into Cancer and Nutrition, and policy-informing evaluations that influenced tobacco, occupational, and infection-related cancer prevention strategies. Proteges and collaborators now occupy leadership roles across institutions including the International Agency for Research on Cancer, national institutes such as the National Cancer Institute, and universities across Europe and North America, perpetuating frameworks for interdisciplinary cancer research.
Category:British epidemiologists Category:Cancer researchers Category:People from Glasgow